Melanoma vaccine cuts recurrence risk 42% in trial

A personalized melanoma vaccine demonstrated a 42% reduction in recurrence or death risk in a trial at the Melanoma Institute Australia. The result marks a notable advance in individualized cancer immunotherapy, though full efficacy and long-term survival data remain pending. This could shift treatment paradigms for high-risk melanoma if confirmed.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works